Human Health Partnering
Human Health Partnering
Search
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Clinical Studies
Clinical Studies
Science Stories
Science and Innovation - Human Health Innovation - Science Stories
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Lung Cancer
Lung Cancer
What Our Partners Say
What Our Partners Say
Gastrointestinal Cancers
Gastrointestinal Cancers
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
Empowering Patients
Empowering Patients
Parasiticides
Science and Innovation - Animal Health Innovation - Parasiticides
Animal Health Partnering
Description Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team
Cancer
Cancer
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
Fostering Science
Science and Innovation - Human Health Innovation - Fostering Science
Depression
Depression
Therapeutics
Science and Innovation - Animal Health Innovation - Therapeutics
Partnering
Partnering
Science & Innovation
Science & Innovation
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Science Focus
Science and Innovation - Human Health Innovation - Science Focus
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
Patient Centricity
Patient Centricity
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study